Assessment of Genetic Diversity of HTLV-1 ORF-I Sequences Collected from Patients with Different Clinical Profiles

Borba, Melina Mosquera Navarro; Farre, Lourdes; Bittencourt, Achiléa Lisboa; Castro-Amarante, Maria Fernanda de; Galvão–Castro, Bernardo; Santos, Luciane Amorim; Araújo, Théssika Hialla Almeida; Alcântara, Luíz Carlos Júnior; Barreto, Fernanda Khouri

doi:10.1089/aid.2019.0127

Cited by 5 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We recognize that the similarities between our patients and those from Latin America and Spain, as well as the distinctions from Japanese patients, may also result from infection with various genotypes of HTLV-1 [ 39 , 40 ]. In Romania, the viral strains belong to the Transcontinental subgroup of the Cosmopolitan a-genotype, similar to other parts of Europe and many regions in Latin America [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Features and Survival Outcome in Aggressive-Type Adult T-Cell Leukemia/Lymphoma Patients: Real-Life Experience of a Single Center from an HTLV-1 Endemic Country

Iordan,

Vlădăreanu,

Mambet

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive T-cell lymphoproliferative disease associated with the human T-cell lymphotropic virus type I (HTLV-1). ATLL is a rare disease, found more frequently in HTLV-1-endemic areas, Romania being one of them. Despite treatment advances, the prognosis remains dismal. We aimed to describe the clinical, biological, and survival outcome features of Romanian patients with aggressive-type ATLL. Materials and Methods: We report the data of a prospective, observational, and unicentric study of all 20 patients diagnosed with lymphoma and acute types of ATLL at our center over the past 12 years. Data were collected from the patients’ medical records. Results: Lymphoma-type ATLL (60%) was more common than acute-type ATLL (40%). Median age at diagnosis was 40.5 years, and most patients were female. Laboratory data revealed significant differences between acute and lymphoma-type ATLL, namely, higher leukocyte (p = 0.02) and lymphocyte counts (p = 0.02) and higher levels of corrected calcium (p = 0.001) in acute-type ATLL. All patients received chemotherapy, and only two underwent allogeneic stem cell transplantation. Only six patients obtained a complete or partial response to chemotherapy, mostly the lymphoma-type ones. The median survival for all patients was 6.37 months, with higher survival in the lymphoma-type ATLL (8.16 months) than in the acute-type (3.60 months). Normal calcium levels (p = 0.011), uric acid (p = 0.005), BUN score (p = 0.000), JCOG-PI moderate risk (p = 0.038), and obtaining complete or partial response (p = 0.037) were associated with higher survival. Conclusion: Aggressive-type ATLL among Romanian patients presents distinct characteristics, including younger age at diagnosis, female predominance, and higher incidence of lymphoma-type ATLL compared to currently reported data. Survival remains very low, with all subtypes experiencing a median survival of less than one year.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Features and Survival Outcome in Aggressive-Type Adult T-Cell Leukemia/Lymphoma Patients: Real-Life Experience of a Single Center from an HTLV-1 Endemic Country

Iordan,

Vlădăreanu,

Mambet

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…Blood samples were collected and peripheral blood mononuclear cell separation was performed on the same day. The DNA was extracted using the DNeasy Blood and Tissue Kit (Qiagen) following the manufacturer's instructions, and the hbz region was amplified through polymerase chain reaction (PCR) cycling, according to the protocol previously published 13 . Amplification was confirmed by agarose gel electrophoresis; PCR products were purified following manufactory instructions (QIAquick PCR Purification Kit; Qiagen) and sequenced by 3500xL Genetic Analyzer (Applied Biosystems) employing the same primers used in amplification.…”

Section: Methodsmentioning

confidence: 99%

Molecular characterization of HTLV‐1 genomic region hbz from patients with different clinical conditions

Cucco

Moraes

Andrade

et al. 2021

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

The human T-cell lymphotropic virus type-1 (HTLV-1) is associated with severe pathologies, such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), adult T-cell leukemia-lymphoma (ATLL), and infective dermatitis associated with the HTLV-1 (IDH). Interestingly, HTLV-1 infection does not necessarily How to cite this article: Cucco MS, de Moraes LEP, de Oliveira Andrade F, et al. Molecular characterization of HTLV-1 genomic region hbz from patients with different clinical conditions.

show abstract

“…Infected individuals can develop HTLV-1-associated pathologies such as adult T-cell leukemia/lymphoma (ATLL in 2-5% of patients), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP in 0.25-3.8% of patients), HTLV-1-associated infectious dermatitis (IDH), and other inflammatory diseases such as uveitis and pneumonitis, or they can be classified as asymptomatic carriers [5][6][7]. The factors involved in the development of a particular clinical manifestation have not yet been elucidated, and HTLV-1-infected individuals remain without specific treatment [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

An overview of sequencing technology platforms applied to HTLV-1 studies: a systematic review

et al. 2021

Self Cite

View full text Add to dashboard Cite

Human T-lymphotropic virus type 1 (HTLV-1) was the first human retrovirus described. The viral factors involved in the different clinical manifestations of infected individuals are still unknown, and in this sense, sequencing technologies can support viral genome studies, contributing to a better understanding of infection outcome. Currently, several sequencing technologies are available with different approaches. To understand the methodological advances in the HTLV-1 field, it is necessary to organize a synthesis by a rigorous review. This systematic literature review describes different technologies used to generate HTLV-1 sequences. The review follows the PRISMA guidelines, and the search for articles was performed in PubMed, Lilacs, Embase, and SciELO databases. From the 574 articles found in search, 62 were selected. The articles showed that, even with the emergence of new sequencing technologies, the traditional Sanger method continues to be the most commonly used methodology for generating HTLV-1 genome sequences. There are many questions that remain unanswered in the field of HTLV-1 research, and this reflects on the small number of studies using next-generation sequencing technologies, which could help address these gaps. The data compiled and analyzed here can help research on HTLV-1, assisting in the choice of sequencing technologies.

show abstract

Assessment of Genetic Diversity of HTLV-1 ORF-I Sequences Collected from Patients with Different Clinical Profiles

Cited by 5 publications

References 15 publications

Clinical Features and Survival Outcome in Aggressive-Type Adult T-Cell Leukemia/Lymphoma Patients: Real-Life Experience of a Single Center from an HTLV-1 Endemic Country

Clinical Features and Survival Outcome in Aggressive-Type Adult T-Cell Leukemia/Lymphoma Patients: Real-Life Experience of a Single Center from an HTLV-1 Endemic Country

Molecular characterization of HTLV‐1 genomic region hbz from patients with different clinical conditions

An overview of sequencing technology platforms applied to HTLV-1 studies: a systematic review

Contact Info

Product

Resources

About